Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conjugate vaccines.

Stephen Lockhart1

  • 1Wyeth Vaccines Research, Huntercombe Lane South, Taplow, Maidenhead SL6 0PH, UK. lockhas@wyeth.com

Expert Review of Vaccines
|January 9, 2004
PubMed
Summary

Conjugate vaccines, like those for Haemophilus influenzae type b, effectively prevent invasive diseases in young children. Lessons learned from their development inform future conjugate vaccine strategies and applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children.

Open forum infectious diseases·2025
Same author

CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds.

Journal of the Pediatric Infectious Diseases Society·2023
Same author

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.

The New England journal of medicine·2023
Same author

Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.

The New England journal of medicine·2023

Area of Science:

  • Immunology and Vaccinology
  • Microbial Pathogenesis and Host Defense
  • Pediatric Infectious Diseases

Background:

  • Conjugate vaccines link bacterial capsular polysaccharides to protein carriers.
  • This linkage converts T-cell-independent responses to T-cell-dependent ones.
  • Proven highly effective against invasive diseases caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis in infants and children.

Purpose of the Study:

  • To review lessons learned from the development of existing conjugate vaccines.
  • To inform the clinical development of future conjugate vaccines.
  • To explore new indications and approaches for conjugate vaccine technology.

Main Methods:

  • Review of existing literature and clinical data on conjugate vaccines.
  • Analysis of factors influencing vaccine efficacy and development.
  • Consideration of immunological principles and vaccine design.

Main Results:

  • Established conjugate vaccines are highly effective in preventing invasive diseases.
  • Key areas for future development include combination vaccines, dose-ranging, and cross-protection.
  • Potential exists for conjugate vaccines against other organisms and for new indications.

Conclusions:

  • The success of current conjugate vaccines provides a strong foundation for future innovations.
  • Further research is needed on correlates of protection, noninvasive disease prevention, and use in diverse age groups.
  • Conjugate vaccine technology remains a dynamic and promising field for infectious disease prevention.

Related Experiment Videos